A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)

NCT03894280 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence

Interventions

DRUG: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
DRUG: SERETIDE DISKUS® 250/50 inhalation powder/GSK
OTHER: Activated Charcoal suspension

Sponsor

Respirent Pharmaceuticals Co Ltd.

Collaborators

[object Object]